中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2013年
18期
1106-1110
,共5页
三阴性乳腺癌%非三阴性乳腺癌%a-B晶体蛋白%靶向治疗
三陰性乳腺癌%非三陰性乳腺癌%a-B晶體蛋白%靶嚮治療
삼음성유선암%비삼음성유선암%a-B정체단백%파향치료
triple negative breast cancer%non-triple negative breast cancer%α-B crystalline protein%targeted therapy
目的:研究a-B晶体蛋白在三阴性乳腺癌(TNBC)中的表达,通过分析a-B晶体蛋白与乳腺癌临床、病理各指标之间的相关性,从而探讨其在TNBC的预后及靶向治疗中的作用。方法:采用免疫组织化学(IHC)S-P法检测30例TNBC,50例非TNBC的石蜡标本切片组织中的a-B晶体蛋白,比较TNBC与非TNBC组织中a-B晶体蛋白表达差异性,对a-B晶体蛋白表达与乳腺癌临床及病理指标间的关系进行相关性分析。结果:a-B晶体蛋白在TNBC中的阳性表达率为66.67%(20/30),明显高于在非TNBC中的表达率42.00%(21/50)(χ2=4.566,P<0.05);a-B晶体蛋白在乳腺癌中的表达与年龄、肿瘤直径、肿瘤分期无明显差异(P>0.05);与有无淋巴结转移、淋巴结转移个数、P53表达、ki-67表达有显著性差异(P<0.05),且呈正相关。a-B晶体蛋白在TNBC中的表达与年龄、肿瘤直径、有无淋巴结转移、淋巴结转移个数、肿瘤分期、P53表达、ki-67表达无相关性(P>0.05)。结论:a-B晶体蛋白的阳性表达在TNBC与非TNBC之间存在差异。a-B晶体蛋白在TNBC中高表达,且表达强度明显高于非TNBC。a-B晶体蛋白与乳腺癌预后不良相关,而a-B晶体蛋白在TNBC中的高表达可能为TNBC预后差的原因之一。
目的:研究a-B晶體蛋白在三陰性乳腺癌(TNBC)中的錶達,通過分析a-B晶體蛋白與乳腺癌臨床、病理各指標之間的相關性,從而探討其在TNBC的預後及靶嚮治療中的作用。方法:採用免疫組織化學(IHC)S-P法檢測30例TNBC,50例非TNBC的石蠟標本切片組織中的a-B晶體蛋白,比較TNBC與非TNBC組織中a-B晶體蛋白錶達差異性,對a-B晶體蛋白錶達與乳腺癌臨床及病理指標間的關繫進行相關性分析。結果:a-B晶體蛋白在TNBC中的暘性錶達率為66.67%(20/30),明顯高于在非TNBC中的錶達率42.00%(21/50)(χ2=4.566,P<0.05);a-B晶體蛋白在乳腺癌中的錶達與年齡、腫瘤直徑、腫瘤分期無明顯差異(P>0.05);與有無淋巴結轉移、淋巴結轉移箇數、P53錶達、ki-67錶達有顯著性差異(P<0.05),且呈正相關。a-B晶體蛋白在TNBC中的錶達與年齡、腫瘤直徑、有無淋巴結轉移、淋巴結轉移箇數、腫瘤分期、P53錶達、ki-67錶達無相關性(P>0.05)。結論:a-B晶體蛋白的暘性錶達在TNBC與非TNBC之間存在差異。a-B晶體蛋白在TNBC中高錶達,且錶達彊度明顯高于非TNBC。a-B晶體蛋白與乳腺癌預後不良相關,而a-B晶體蛋白在TNBC中的高錶達可能為TNBC預後差的原因之一。
목적:연구a-B정체단백재삼음성유선암(TNBC)중적표체,통과분석a-B정체단백여유선암림상、병리각지표지간적상관성,종이탐토기재TNBC적예후급파향치료중적작용。방법:채용면역조직화학(IHC)S-P법검측30례TNBC,50례비TNBC적석사표본절편조직중적a-B정체단백,비교TNBC여비TNBC조직중a-B정체단백표체차이성,대a-B정체단백표체여유선암림상급병리지표간적관계진행상관성분석。결과:a-B정체단백재TNBC중적양성표체솔위66.67%(20/30),명현고우재비TNBC중적표체솔42.00%(21/50)(χ2=4.566,P<0.05);a-B정체단백재유선암중적표체여년령、종류직경、종류분기무명현차이(P>0.05);여유무림파결전이、림파결전이개수、P53표체、ki-67표체유현저성차이(P<0.05),차정정상관。a-B정체단백재TNBC중적표체여년령、종류직경、유무림파결전이、림파결전이개수、종류분기、P53표체、ki-67표체무상관성(P>0.05)。결론:a-B정체단백적양성표체재TNBC여비TNBC지간존재차이。a-B정체단백재TNBC중고표체,차표체강도명현고우비TNBC。a-B정체단백여유선암예후불량상관,이a-B정체단백재TNBC중적고표체가능위TNBC예후차적원인지일。
Objective: To investigate the expression of α-B crystalline in triple-negative breast cancer (TNBC) and discuss its role in the prognosis and targeted therapy of TNBC by analyzing the correlation amongα-B crystalline and the clinico-pathological indi-ces of breast cancer. Methods:Immunohistochemistry SP assay was used to determineα-B crystalline expression in paraffin-embedded specimens of 30 cases of TNBC and 50 cases of non-TNBC tissues. The differences in protein expressions among tissues were com-pared, and correlation analysis was performed to determine the relationship between protein expression and clinico-pathological indi-ces. Results:The positive expression rate ofα-B crystalline was 66.67%in TNBC (20/30) and 42.00%in non-TNBC (21/50), which in-dicates that the expression is significantly higher in TNBC than in the non-TNBC tissues (χ2=4.566, P<0.05). The expression ofα-B crystalline in breast cancer has no significant difference in terms of age, tumor diameter, and cancer stage (P>0.05), but exhibits a differ-ence in terms of lymph node metastasis and the number of metastasized lymph nodes [P53, Ki67 (P<0.05)], which presents a positive correlation (r=0.251). Theα-B crystalline expression in TNBC has no significant difference among indices such as age, tumor diameter, nodal metastasis, number of metastasis, P53, cancer stage, and Ki67 (P>0.05). Conclusion:Significant differences were found inα-B crystalline expression between TNBC and non-TNBC.α-B crystalline is highly expressed in TNBC tissues, and the expression is signif-icantly higher in TNBC tissues than that in non-TNBC tissues.α-B crystalline is associated with poor prognosis of breast cancer. Conse-quently, the overexpression ofα-B crystalline in TNBC may be a reason for unfavorable TNBC prognosis.